Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90 Y-DOTA

Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90 Y-DOTA

© 2020 American Association for Cancer Research. Pretargeted radioimmunotherapy (PRIT) has been investigated as a multi-step approach to decrease relapse and toxicity for high-risk acute myeloid leukemia (AML). Relevant factors including endogenous biotin and immunogenicity, however, have limited th...

Full description

Bibliographic Details
Main Authors: Orozco, Johnnie J, Kenoyer, Aimee L, Lin, Yukang, O'Steen, Shyril, Guel, Rosario, Nartea, Margaret E, Hernandez, Alexandra H, Hylarides, Mark D, Fisher, Darrell R, Balkin, Ethan R, Hamlin, Donald K, Wilbur, D Scott, Orcutt, Kelly D, Wittrup, K Dane, Green, Damian J, Gopal, Ajay K, Till, Brian G, Sandmaier, Brenda, Press, Oliver W, Pagel, John M
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Language:English
Published: American Association for Cancer Research (AACR) 2021
Online Access:https://hdl.handle.net/1721.1/133436

Internet

https://hdl.handle.net/1721.1/133436

Similar Items